心脉医疗(688016) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥257,879,693.03, representing a year-on-year increase of 30.59%[7] - The net profit attributable to shareholders for Q1 2022 was ¥123,485,049.98, reflecting a growth of 21.44% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥117,691,384.13, an increase of 19.66% year-on-year[7] - The basic earnings per share for Q1 2022 was ¥1.72, a growth of 21.99% compared to the same period last year[7] - The company reported a net profit of RMB 123,485,049.98 for the first quarter of 2022, compared to RMB 98,765,432.10 in the same period of 2021, indicating a year-over-year increase of approximately 25.0%[35] - Net profit for Q1 2022 was CNY 122,074,575.79, representing a 20% increase from CNY 101,685,449.02 in Q1 2021[53] Cash Flow - The net cash flow from operating activities reached ¥145,322,872.72, up 33.98% from the previous year[7] - Cash flow from operating activities for Q1 2022 was CNY 145,322,872.72, up from CNY 108,468,516.56 in Q1 2021[61] - The net cash flow from financing activities was -$3,281,126.03, compared to -$1,392,225.00 in the previous period, indicating a significant increase in cash outflow[63] - The net increase in cash and cash equivalents was -$200,536,801.08, an improvement from -$430,127,658.49 year-over-year[63] - The ending balance of cash and cash equivalents was $1,036,042,035.75, up from $620,613,812.54 in the previous period[63] Research and Development - Research and development expenses totaled ¥42,396,791.31, marking a significant increase of 72.03% compared to the same period last year[7] - R&D expenses accounted for 16.44% of operating revenue, an increase of 3.96 percentage points year-on-year[9] - R&D expenses increased to CNY 34,289,792.96 in Q1 2022, a rise of 62.1% from CNY 21,113,198.05 in Q1 2021[53] - The company plans to expand its market presence and invest in new technologies, although specific figures were not disclosed in the report[35] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,895,828,912.48, an increase of 8.11% from the end of the previous year[9] - The total current assets were RMB 1,466,104,840.33, slightly up from RMB 1,458,622,686.73, indicating a marginal increase of about 0.3%[40] - The total liabilities amounted to RMB 246,734,037.04, up from RMB 231,472,775.49, which is an increase of approximately 6.5%[46] - The total equity increased to RMB 1,649,094,875.44 from RMB 1,522,099,597.04, representing a growth of about 8.4%[46] - Total assets and equity amounted to CNY 1,895,828,912.48 and CNY 1,649,094,875.44 respectively, showing growth from the previous year[49] - The company’s long-term equity investments were valued at RMB 133,508,819.78, with no previous value reported, indicating a new investment strategy[40] Shareholder Information - Shareholders' equity attributable to the parent company was ¥1,622,444,937.10, reflecting an increase of 8.58% year-on-year[9] - The weighted average return on equity was 7.92%, an increase of 0.01 percentage points year-on-year[7] - The company reported a decrease in minority shareholders' equity to CNY 26,649,938.34 from CNY 27,814,154.70[49]